Navigation Links
For Atrial Fibrillation, Surveyed Experts Indicate That Multaq, Celivarone and ATI-2042 Have Advantages Over Propafenone in the Maintenance of Normal Sinus Rhythm
Date:4/21/2009

Multaq Will Earn Decision Resources' Clinical Gold Standard Status for Atrial Fibrillation in 2012, According to a New Report from Decision Resources

WALTHAM, Mass., April 21 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed cardiologists identify a therapy's effect on mortality as the attribute that most influences their prescribing decisions in maintenance of normal sinus rhythm in atrial fibrillation. Clinical data and the opinions of interviewed thought leaders indicate that Sanofi-Aventis's Multaq and celivarone, and Aryx Therapeutics' ATI-2042 have advantages in this attribute over propafenone (GlaxoSmithKline/Abbott's Rythmol/Rythmonorm, generics), the sales-leading antiarrhythmic agent in the market.

The new report entitled Atrial Fibrillation: Opportunity Awaits Antiarrhythmics with Improved Safety and Anticoagulants Without Routine Monitoring also finds that an anticoagulant for the prevention of stroke in atrial fibrillation that does not require routine monitoring would earn a 53 percent patient share in the United States and a 55 percent patient share in Europe, according to surveyed U.S. and European cardiologists.

In 2008, Decision Resources' proprietary clinical gold standard for the maintenance of normal sinus rhythm in atrial fibrillation was amiodarone (Sanofi-Aventis/Wyeth's Cordarone, generics). Based on available data and expert opinion, Multaq will earn gold standard status for maintenance of normal sinus rhythm in atrial fibrillation in 2012, following its approval for the indication in 2009. Additionally, following its approval in 2014, ATI-2042 will earn gold-standard status for the indication in 2017.

"Multaq and ATI-2042 have competitive advantages over other emerging therapies because they have been designed to have efficacy similar to that of amiodarone but without its side effects," said Decision Resources Analyst Samira Benyoucef, Ph.D. "Because they are free of thyroid and pulmonary toxicity--the main adverse effects constraining amiodarone's widespread use--Multaq and ATI-2042 offer a significant safety advantage over amiodarone."

About the Report

Atrial Fibrillation: Opportunity Awaits Antiarrhythmics with Improved Safety and Anticoagulants Without Routine Monitoring is a DecisionBase 2009 report. DecisionBase 2009 is a decision-support tool that provides in-depth analysis of unmet need, physician expectations of new therapies and commercial dynamics to help pharmaceutical companies optimize their investments in drug development.

The report can be purchased by contacting Decision Resources. Members of the media may request an interview with an analyst.

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

    For more information, contact:

    Decision Resources                              Decision Resources, Inc.
    Christopher Comfort                             Elizabeth Marshall
    781-296-2597                                    781-296-2563
    ccomfort@dresources.com                         emarshall@dresources.com


'/>"/>
SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Larger Men at Greater Risk for Atrial Fibrillation
2. Big men more susceptible to atrial fibrillation
3. For Prevention of Stroke, Surveyed Cardiologists and PCPs Expect to Prescribe Xarelto to Approximately One-Third of Newly-Diagnosed Atrial Fibrillation Patients
4. Boehringer Ingelheim Plans to Launch U.S. Registry to Assess the State of Anticoagulation Therapy for Stroke Prevention in Patients with Non-Valvular Atrial Fibrillation
5. Final Patient Completes Treatment In Boehringer Ingelheims RE-LY(R) Study, The Largest Atrial Fibrillation Outcomes Trial To Date
6. Austin, Texas, Physicians Second in Nation to Perform New Procedure for Difficult-to-Treat Atrial Fibrillation Cases
7. Increasing Use of Ablation to Treat Atrial Fibrillation
8. Defect in Gene Tied to Atrial Fibrillation
9. Novel Anticoagulants Will Garner More Than Three-Quarters of the Atrial Fibrillation Drug Market in 2017
10. Innovative Atrial Fibrillation (AF) Catheter Ablation System From Ablation Frontiers is Subject of Two Abstracts at Heart Rhythm Congress UK
11. Novel imaging approach may assist in predicting success of treatment for atrial fibrillation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... 2017 , ... Global Healthcare Management’s 4th Annual Kids Fun Run brought out ... free event, sponsored by Global Healthcare Management’s CEO, Jon Letko, is aimed at getting ... children of all ages; it is a non-competitive, non-timed event, which is all about ...
(Date:10/13/2017)... ... October 13, 2017 , ... “America On The Brink”: the Christian history of ... Brink” is the creation of published author, William Nowers. Captain Nowers and his ... veteran, he spent thirty years in the Navy. Following his career as a ...
(Date:10/12/2017)... CITY, Fla. (PRWEB) , ... October 12, 2017 , ... ... cold therapy products, announced today the introduction of an innovative new design of the ... multipurpose pad so you get maximum comfort while controlling your pain while using cold ...
(Date:10/12/2017)... ... , ... HMP , a leader in healthcare events and education, today announced ... Award for ‘Best B-to-B Healthcare Website.’ Winners were announced during the Eddie & Ozzie ... competition recognizes editorial and design excellence across a range of sectors. This year’s program ...
(Date:10/12/2017)... ... 12, 2017 , ... In the United States, single-family home ... states—like New York, New Jersey, Massachusetts, Texas, Virginia, Connecticut, and California—the average is ... low property-tax rates, which contributes to the relatively lower cost of living in ...
Breaking Medicine News(10 mins):
(Date:10/11/2017)... , Oct. 11, 2017  Caris Life Sciences ® ... fulfilling the promise of precision medicine, today announced that ... Caris, Precision Oncology Alliance™ (POA) as its 17 th ... the St. Jude Crosson Cancer Institute will help develop ... use of tumor profiling, making cancer treatment more precise ...
(Date:10/10/2017)... 10, 2017   West Pharmaceutical Services, Inc. ... injectable drug administration, today shared the results of a ... improving the intradermal administration of polio vaccines. The study ... in May 2017 by Dr. Ondrej Mach , ... Health Organization (WHO), and recently published in the journal ...
(Date:10/4/2017)... , Oct. 4, 2017  According to the Centers for Disease Control ... of October . PhysicianOne Urgent Care is helping communities across ... NY , by offering no-cost* flu shots through the end of ... by certain health insurance regulations. ... best time to get a flu shot is by the end of ...
Breaking Medicine Technology: